welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy
study id #: NCT01753804
condition: Duchenne Muscular Dystrophy
To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the development of rare exons for which formal controlled trials are not feasible.
intervention: Observational study
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: September 1, 2012
estimated completion: October 1, 2016
size / enrollment: 269
This is a prospective study. All DMD patients that fulfil the inclusion/exclusion criteria are eligible although the study is weighted towards ambulant subjects aged 3 years or older. There will be 7 study visits and subjects will be in the study for a maximum of 3 years. Visits will occur every 6 months (+/- 1 month).
Up to 250 DMD subjects planned in the following categories :-
• 75 % ambulant subjects aged between 3 and 18 years at study entry;
• 25% non-ambulant subjects with a maximum age of 18 years at study entry.
Subjects will be asked to perform muscle testing assessment with a clinical evaluator, such as walking for 6 minutes, climb stairs, breathe in a tube, see how they can move their arms and legs. They will be asked questions about how they feel overall and perform daily activities. These measurements will be assessed every 6 months.
Urine and blood samples will be collected once a year to measure biomarkers that will allow to have a better overview of DMD.
- 6 minute walk distance [Time Frame: Change from visit 1 walking distance]
Participants are asked to walk at their own preferred speed on a fixed distance for 6 minutes. Subjects are warned of the time and that they may stop earlier if they feel unable to continue. Total distance walked within 6 minutes (or until stopping) is recorded.
• Diagnosis of DMD resulting from a mutation in the DMD gene confirmed by a state of the art DNA diagnostic technique covering all DMD gene exons.
• Age 3 - 18 years
• Willing and able to comply with protocol requirements
• Life expectancy of at least 3 years
• Able to give informed assent and/or consent in writing signed by the subject and/or parent(s)/legal guardian (according to local regulations)
• Current participation in a clinical study with an Investigational Medicinal Product (IMP)
• Participation within the previous 1 month in a clinical study with an IMP
Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Musc...Catabasis Pharmaceuticals, Inc. (NASDAQ:...
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyThis is a Phase 1, double-blind, placebo...
A Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial...Sarepta Therapeutics, Inc., a commercia...
Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on CorticosteroidsThe purpose of the study is to assess th...
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
Upper arm, pulmonary and cardiac magnetic resonance imaging for relative disease status in Duchenne muscular dystrop...Objective: To simultaneously assess the...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...